Peer-influenced content. Sources you trust. No registration required. This is HCN.

Renal & Urology NewsReal-World Data Confirm Efficacy of (177)Lutetium PSMA-617 for mCRPC

The recent study by Medical University Innsbruck reports encouraging results regarding the effectiveness of 177Lutetium PSMA-617 (177Lu PSMA) in treating metastatic castration-resistant prostate cancer (mCRPC). The data reveals promising decreases in PSA levels and gives clinicians an actionable early marker of therapeutic response.

HCN Medical Memo
The significance of this real-world study is its validation of 177Lu PSMA as a viable treatment option for mCRPC patients. The study provides actionable insights like early PSA decrease markers that can easily be incorporated into clinical practice. It serves as a useful adjunct to the more controlled environment of clinical trials, offering evidence that this treatment may also be effective in more diverse and complex cases.

Key Points:
  • The retrospective study involved 233 mCRPC patients at eight high-volume European centers.
  • A PSA decrease of 30% or more after the first two cycles served as an early indicator of treatment response, as noted by Isabel Heidegger, MD, and colleagues.
  • In the progression of treatment cycles, 41.7%, 63.5%, and 77.8% of patients exhibited a 30% or greater decrease in PSA after the first, second, and third cycles, respectively.
  • 33.7% of patients had an imaging-based response, and 13.4% had stable disease. A PSA rise after the first cycle significantly correlated with a 2.1-fold higher risk of disease progression.
  • The median time to progression was 5 months, lower than the 8.7 months in the phase 3 VISION trial, partly attributed to the study’s inclusion of heavily pretreated patients and those with poor performance statuses.
Additional Points:
  • More than 80% of the patients had grade group 4 or 5 cancer at the time of primary diagnosis.
  • The median time until the initiation of consecutive anti-neoplastic treatment was 8.5 months.
  • A gamma-glutamyl transferase level of 31 U/L or less was significantly correlated with a 1.5 times higher risk of progression in patients without visceral metastases.

By the end of the study, 48% of patients were alive, 48% had died from prostate cancer, and 4% had died from other causes.

More on Prostate Cancer

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form